Age and Gender Effects on the Pharmacokinetics of BAY85-3934

• Area under the plasma concentration vs time curve from zero to infinity after single (first) dose of BAY85-3934 [ Time Frame: Measured over 72 hours after dosing ] [ Designated as safety issue: No ]
• Maximum drug concentration in plasma after single dose administration of BAY85-3934 [ Time Frame: Measured over 72 hours after dosing ] [ Designated as safety issue: No ]
• Safety and tolerability of BAY 85-3934 after single dose administration as determined by physical examination (changes from baseline) [ Time Frame: Measured over 96 hours after dosing ] [ Designated as safety issue: Yes ]
• Safety and tolerability of BAY 85-3934 after single dose administration as determined by adverse events monitoring (number of subjects with a specific event) [ Time Frame: Measured over 96 hours after dosing ] [ Designated as safety issue: Yes ]
• Safety and tolerability of BAY 85-3934 after single dose administration as determined by electrocardigram and and vital sign measurememnt (changes from baseline) [ Time Frame: Measured over 72 hours after dosing ] [ Designated as safety issue: Yes ]
• Safety and tolerability of BAY 85-3934 after single dose administration as determined by laboratory testing (changes from baseline) [ Time Frame: Measured over 48 hours after dosing ] [ Designated as safety issue: Yes ]

• Pharmacodynamic effects on erythropoietin as the change from baseline at 48 hours [ Time Frame: 48 hours post dose ] [ Designated as safety issue: No ]
• Pharmacodynamic effects on reticulocytes as the change from baseline at 96 hours [ Time Frame: 96 hours post dose ] [ Designated as safety issue: No ]
• Pharmacodynamic effects on hemoglobin as the change from baseline at 48 hours [ Time Frame: 48 hours post dose ] [ Designated as safety issue: No ]
• Pharmacodynamic effects on hematocrit as the change from baseline at 96 hours [ Time Frame: 96 hours post dose ] [ Designated as safety issue: No ]
• Pharmacodynamic effects on vascular endothelial growth factor (VEGF) as the change from baseline at 96 hours [ Time Frame: 96 hours post dose ] [ Designated as safety issue: No ]

Single dose study of BAY85-3934 compared to placebo in young/elderly male and female healthy subjects. The main focus of the study is to determine if the pharmacokinetics (drug levels in blood) of BAY85-3934 is similar or not in the four subject groups. Qualifying subjects will be dosed with a single tablet of BAY85-3934 (or placebo) and blood will be drawn over 4 days. The safety and tolerability of BAY85-3934 compared to placebo will also be evaluated over the 5 days of the study.

• Drug: BAY85-3934
  Single doses of 20 mg BAY85-3934 as tablet
• Drug: Placebo
  Single dose of placebo tablet matching the 20 mg BAY85-3934 tablet

• Experimental: Arm 1
  Intervention: Drug: BAY85-3934
• Placebo Comparator: Arm 2
  Intervention: Drug: Placebo

Inclusion Criteria:

• No diagnosis of any specific disease or condition
• Subjects are expected to be in good general health for their respective age range
• Male or female gender
• Age subgroups: 1) 18 to 45 years (inclusive) and 2) 65 to 85 years (inclusive)
• Racial group: Caucasian

Exclusion Criteria:

• Pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal. This includes moderate and severe renal impairment (on dialysis or not), and moderate or severe hepatic disease.
• Clinically relevant findings in the physical examination